滤泡性和乳头状甲状腺癌进展的小鼠模型。
Mouse models of follicular and papillary thyroid cancer progression.
机构信息
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine Bronx, NY, USA.
出版信息
Front Endocrinol (Lausanne). 2012 Jan 10;2:119. doi: 10.3389/fendo.2011.00119. eCollection 2011.
Abstract
A significant number of well-differentiated thyroid cancers progress or recur, becoming resistant to current therapeutic options. Mouse models recapitulating the genetic and histological features of advanced thyroid cancer have been an invaluable tool to dissect the mechanisms involved in the progression from indolent, well differentiated tumors to aggressive, poorly differentiated carcinomas, and to identify novel therapeutic targets. In this review, we focus on the lessons learned from models of epithelial cell-derived thyroid cancer showing progression from hyperplastic lesions to locally invasive and metastatic carcinomas.
摘要
大量分化良好的甲状腺癌会进展或复发，对当前的治疗选择产生耐药性。能够重现晚期甲状腺癌遗传和组织学特征的小鼠模型，是解析从惰性、分化良好的肿瘤向侵袭性、低分化癌进展过程中涉及的机制，并确定新的治疗靶点的宝贵工具。在这篇综述中，我们重点介绍了源自上皮细胞的甲状腺癌模型中所获得的经验教训，这些模型显示了从增生性病变向局部侵袭性和转移性癌的进展。
相似文献
1
Mouse models of follicular and papillary thyroid cancer progression.滤泡性和乳头状甲状腺癌进展的小鼠模型。
Front Endocrinol (Lausanne). 2012 Jan 10;2:119. doi: 10.3389/fendo.2011.00119. eCollection 2011.
2
Modeling anaplastic thyroid carcinoma in the mouse.在小鼠中模拟间变性甲状腺癌。
Horm Cancer. 2015 Feb;6(1):37-44. doi: 10.1007/s12672-014-0208-8. Epub 2014 Nov 25.
3
4
Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas.致命性非间变性滤泡细胞源性甲状腺癌的临床病理特征
Thyroid. 2016 Nov;26(11):1588-1597. doi: 10.1089/thy.2016.0247. Epub 2016 Sep 7.
5
Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid.甲状腺高分化和低分化滤泡癌之间的阈值应设定在哪里。
Endocr Pathol. 2004 Winter;15(4):297-305. doi: 10.1385/ep:15:4:297.
6
Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.甲状腺分化型癌的预后因素及治疗策略
Endocr J. 2009;56(2):177-92. doi: 10.1507/endocrj.k08e-166. Epub 2008 Aug 13.
7
The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression.高分化甲状腺癌与岛状或间变性甲状腺癌的关联；肿瘤进展中去分化的证据。
Endocr Pathol. 1993 Dec;4(4):215-221. doi: 10.1007/BF02915464.
8
The Current Histologic Classification of Thyroid Cancer.甲状腺癌的现行组织学分类。
Endocrinol Metab Clin North Am. 2019 Mar;48(1):1-22. doi: 10.1016/j.ecl.2018.10.001.
9
Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities.滤泡细胞甲状腺癌的分子和遗传标志物：病因学及诊断和治疗机会。
Adv Exp Med Biol. 2013;779:309-26. doi: 10.1007/978-1-4614-6176-0_14.
10
Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.由 STRN-ALK 表达和 p53 缺失驱动的甲状腺癌进展和去分化的小鼠模型：两种低分化癌存在的证据。
Thyroid. 2019 Oct;29(10):1425-1437. doi: 10.1089/thy.2019.0284. Epub 2019 Aug 16.
引用本文的文献
1
Investigating papillary thyroid cancer risk factors among women living at the central region of Iran: a case-control study.伊朗中部地区女性甲状腺乳头状癌危险因素调查：一项病例对照研究。
BMC Endocr Disord. 2025 Jan 16;25(1):12. doi: 10.1186/s12902-025-01833-3.
2
Molecular therapeutics for anaplastic thyroid cancer.间变性甲状腺癌的分子治疗。
Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25.
3
Mouse models of thyroid cancer: A 2015 update.甲状腺癌小鼠模型：2015年更新
Mol Cell Endocrinol. 2016 Feb 5;421:18-27. doi: 10.1016/j.mce.2015.06.029. Epub 2015 Jun 27.
4
Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.通过对甲状腺癌小鼠模型的分析揭示了人类甲状腺滤泡性腺瘤和癌之间的分子差异。
Endocrinology. 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013-1028. Epub 2013 Jun 10.
本文引用的文献
1
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.CXCR4 的表达与甲状腺乳头状癌的肿瘤浸润程度和 BRAF 状态相关。
Mod Pathol. 2012 Jan;25(1):46-55. doi: 10.1038/modpathol.2011.140. Epub 2011 Sep 9.
2
Classification of thyroid follicular cell tumors: with special reference to borderline lesions.甲状腺滤泡细胞肿瘤的分类：特别关注交界性病变。
Endocr J. 2012;59(1):1-12. doi: 10.1507/endocrj.ej11-0184. Epub 2011 Sep 9.
3
Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size.术前促甲状腺激素血清浓度从良性甲状腺结节逐渐升高至甲状腺微小乳头状癌，然后再升高至更大尺寸的甲状腺乳头状癌。
J Thyroid Res. 2012;2012:530721. doi: 10.1155/2012/530721. Epub 2011 Jul 19.
4
Therapeutic outcomes of papillary thyroid cancer patients in different risk groups.不同危险分层的甲状腺乳头状癌患者的治疗效果。
Oncology. 2011;80(1-2):123-9. doi: 10.1159/000328912. Epub 2011 Jun 14.
5
Raf kinases in cancer-roles and therapeutic opportunities.Raf 激酶在癌症中的作用和治疗机会。
Oncogene. 2011 Aug 11;30(32):3477-88. doi: 10.1038/onc.2011.160. Epub 2011 May 16.
6
Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer.Akt1 缺失可延缓甲状腺癌小鼠模型中的肿瘤进展、血管侵犯和远处转移。
Oncogene. 2011 Oct 20;30(42):4307-15. doi: 10.1038/onc.2011.136. Epub 2011 May 2.
7
Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.突变激活的 BRAF(V600E)可诱发成年小鼠的甲状腺乳头癌。
Cancer Res. 2011 Jun 1;71(11):3863-71. doi: 10.1158/0008-5472.CAN-10-4463. Epub 2011 Apr 21.
8
Papillary thyroid carcinoma: an update.甲状腺乳头状癌：更新。
Mod Pathol. 2011 Apr;24 Suppl 2:S1-9. doi: 10.1038/modpathol.2010.129.
9
Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.BRAF 诱导的甲状腺癌的进展与上皮-间充质转化有关，需要同时激活 MAP 激酶和 TGFβ 信号通路。
Oncogene. 2011 Jul 14;30(28):3153-62. doi: 10.1038/onc.2011.44. Epub 2011 Mar 7.
10
Targeting p27Kip1 protein: its relevance in the therapy of human cancer.靶向 p27Kip1 蛋白：其在人类癌症治疗中的相关性。
Expert Opin Ther Targets. 2011 Jun;15(6):677-93. doi: 10.1517/14728222.2011.561318. Epub 2011 Feb 28.
Zotero 插件